Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human SELE/E-selectin/CD62E-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
Endotoxin: |
Please contact us for more information. |
Immunoreactivity: |
Measured by the ability of the immobilized protein to support the adhesion of U937 human histiocytic lymphoma cells. When 5 x 104cells/well are added to human E-Selectin/Fc Chimera coated plates (2 Mu g/mL with 100 Mu L/well) , approximately 40-50% w |
Gene Symbol: |
SELE |
Gene ID: |
6401 |
Uniprot ID: |
LYAM2_HUMAN |
Immunogen: |
Recombinant Human SELE/E-selectin/CD62E Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Trp22-Pro556) of human E-Selectin/CD62E (Accession #NP_000441.2) fused with a 6×His tag at the C-terminus. |
Function | Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis. |
Protein Name | E-SelectinCd62 Antigen-Like Family Member EEndothelial Leukocyte Adhesion Molecule 1Elam-1Leukocyte-Endothelial Cell Adhesion Molecule 2Lecam2Cd Antigen Cd62e |
Database Links | Reactome: R-HSA-202733 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | E-Selectin proteinCd62 Antigen-Like Family Member E proteinEndothelial Leukocyte Adhesion Molecule 1 proteinElam-1 proteinLeukocyte-Endothelial Cell Adhesion Molecule 2 proteinLecam2 proteinCd Antigen Cd62e proteinSELE proteinELAM1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance